Literature DB >> 22227660

PDGF-B exploits stromal EPO.

Lisa M McGinnis, Calvin J Kuo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22227660     DOI： 10.1038/nm.2623

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

Review 1.  American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Authors:  J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Murat O Arcasoy; Jerry L Spivak; Charles L Bennett; Julia Bohlius; Darren Evanchuk; Matthew J Goode; Ann A Jakubowski; David H Regan; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 2.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises.

Authors:  Annika Armulik; Guillem Genové; Christer Betsholtz
Journal:  Dev Cell       Date:  2011-08-16       Impact factor: 12.270

3.  PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.

Authors:  Yuan Xue; Sharon Lim; Yunlong Yang; Zongwei Wang; Lasse Dahl Ejby Jensen; Eva-Maria Hedlund; Patrik Andersson; Masakiyo Sasahara; Ola Larsson; Dagmar Galter; Renhai Cao; Kayoko Hosaka; Yihai Cao
Journal:  Nat Med       Date:  2011-12-04       Impact factor: 53.440

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

Authors:  M P Simon; F Pedeutour; N Sirvent; J Grosgeorge; F Minoletti; J M Coindre; M J Terrier-Lacombe; N Mandahl; R D Craver; N Blin; G Sozzi; C Turc-Carel; K P O'Brien; D Kedra; I Fransson; C Guilbaud; J P Dumanski
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

Review 6.  Erythropoietin in cancer patients: pros and cons.

Authors:  Mario Dicato; Laurent Plawny
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

Review 7.  Erythropoietin: a hormone with multiple functions.

Authors:  Matilde Lombardero; Kalman Kovacs; Bernd W Scheithauer
Journal:  Pathobiology       Date:  2011-04-05       Impact factor: 4.342

Review 8.  Recent insights into PDGF-induced gliomagenesis.

Authors:  Filippo Calzolari; Paolo Malatesta
Journal:  Brain Pathol       Date:  2009-09-25       Impact factor: 6.508

9.  Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia.

Authors:  Michael S Wiesener; Philine Münchenhagen; Markus Gläser; Bettina A Sobottka; Karl X Knaup; Katrin Jozefowski; Jan Steffen Jürgensen; Jan Roigas; Christina Warnecke; Hermann-Josef Gröne; Patrick H Maxwell; Carsten Willam; Kai-Uwe Eckardt
Journal:  Int J Cancer       Date:  2007-12-01       Impact factor: 7.396

Review 10.  Nonrenal regulation of EPO synthesis.

Authors:  Alexander Weidemann; Randall S Johnson
Journal:  Kidney Int       Date:  2009-01-21       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.